Topics

Articles

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures. 

A Behind-the-Scenes Look at Drug Price Markups 

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.  

AbbVie Invests an Additional $223 Million in Singapore Manufacturing Plant

The definitive merger agreement was reached in October 2023, with Bristol Myers Squibb acquiring Mirati for $58 per share in cash, for a total equity value of $4.8 billion.

Bristol Myers Squibb Grows Oncology Pipeline With Completion of Mirati Acquisition

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Bora Pharmaceuticals Completes $210 Million Purchase of Upsher-Smith 

Acquisition is expected to offer life sciences clients a boost in expertise and insight. 
 

Evaluate Purchases J+D Forecasting 

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector. 

A Closer Look at PBM Spread Pricing

How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.

Strategic Insight and Forecasting: From Pipeline to Pharmacy

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients. 

How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital Therapeutics

MoU aims to align the pharmaceutical and cold chain sectors by boosting operations. 

Pharma.Aero, Cool Chain Association Partner Up on Pharmaceutical Shipping 

Pfizer said that the addition of Seagen to its current operations could add more than $10 billion in risk-adjusted revenues by 2030.

Business and Finance